Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28284592 | 0.80 | AKR1B1 (0.41) | RENKCNH2SMPD1ALDH1A1AKR1B1 | |
| SCHEMBL2808494 | 0.79 | REN (0.45) | RENL3MBTL1 | |
| SCHEMBL17986704 | 0.77 | ALDH1A1 (0.41) | ALDH1A1AKR1B1F2L3MBTL1 | |
| SCHEMBL31621523 | 0.77 | ALDH1A1 (0.41) | ALDH1A1AKR1B1F2L3MBTL1 | |
| SCHEMBL2094194 | 0.76 | CYP1A2 (0.47) | ALDH1A1AKR1B1SIGMAR1 | |
| SCHEMBL27774924 | 0.74 | NPC1 (0.39) | ALDH1A1AKR1B1 | |
| SCHEMBL2805685 | 0.74 | AMPD3 (0.43) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1068764 | 0.74 | AKR1B1 (0.43) | RENKCNH2SMPD1ALDH1A1AKR1B1 | |
| SCHEMBL6045402 | 0.73 | F2 (0.39) | ALDH1A1AKR1B1F2L3MBTL1 | |
| SCHEMBL2805447 | 0.73 | NPC1 (0.38) | RENALDH1A1CYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885KCNH2 39/4885SMPD1 3108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.